Immunitybio, Inc.

This study tests whether adding a combination of immunotherapy drugs (aldoxorubicin, N-803, and PD-L1 t-haNK) to standard chemotherapy can help people with advanced pancreatic cancer live longer without their disease getting worse. About 328 adults with locally advanced or metast…

This early-stage trial tests a new drug called IBRX-042 in 12 people with HPV-related cancers that have come back or worsened. The main goal is to find the safest dose and understand side effects. Participants get three injections, one every three weeks, and are closely monitored…

This study was designed to test whether adding an experimental drug (nogapendekin alfa inbakicept) and special immune cells (iNKT cells) to standard care could help critically ill adults with severe pneumonia, sepsis, or acute respiratory distress syndrome survive longer. The tri…

This study aimed to test whether adding the drug ANKTIVA to standard BCG treatment works better than BCG alone for people with a high-grade, early-stage bladder cancer called NMIBC. The trial was planned for adults who had not received BCG before or had limited exposure. However,…

This study tests a new treatment for people with a type of bladder cancer that has not improved with standard therapy. The treatment combines a standard immunotherapy (BCG) with an experimental drug (N-803), both given directly into the bladder through a catheter. The goal is to …

This study tests whether adding the drug ALT-803 to standard BCG therapy works better than BCG alone for people with a high-grade form of bladder cancer that hasn't invaded muscle. About 369 participants will receive either the combination or BCG alone. The goal is to see if the …

This early-phase study tests a new treatment using a patient's own immune cells (called M-CENK) plus a booster drug (N-803) for people with advanced solid tumors that have spread. The main goal is to check safety and find the right dose. About 50 adults with either newly diagnose…

This study was designed to see if adding two immune treatments (NAI and iNKT cells) to standard care could help critically ill adults with severe pneumonia, sepsis, or lung failure recover. It planned to enroll ICU patients and follow them for 90 days. However, the study was with…

This study was designed for men with high-risk prostate cancer who are scheduled for prostate removal surgery. It planned to give a combination of three immunotherapy drugs (N-803, ETBX-071, and M-CENK) both before and after surgery to see if it could help prevent the cancer from…

This study tests a new combination of immune-boosting drugs for people with advanced solid tumors (like lung, bladder, or skin cancer) whose cancer stopped responding to standard immunotherapy. About 40 participants will receive a novel drug called NAI along with other therapies …

This study was designed for men with high-risk prostate cancer who cannot have surgery. It planned to combine three experimental drugs (N-803, ETBX-071, and M-CENK) with radiation to boost the immune system's attack on cancer. Researchers aimed to see if the treatment could elimi…

This study follows 6 patients who previously received an experimental treatment (N-803 plus BCG) for non-muscle invasive bladder cancer. Researchers will collect long-term data on survival, cancer recurrence, and test results to see how well the treatment worked over time. No new…